promising development from translational or perhaps anti-translational research in breast cancer有前途的发展从平移或者anti-translational研究乳腺癌.pdfVIP

Retsky et al. Clinical and Translational Medicine 2012, 1:17 /content/1/1/17 RESEARCH Open Access Promising development from translational or perhaps anti-translational research in breast cancer 1,2* 3 4 5 5 6 Michael Retsky , Romano Demicheli , William JM Hrushesky , Patrice Forget , Marc De Kock , Isaac Gukas , 1 7 8 9 Rick A Rogers , Michael Baum , Katharine Pachmann and Jayant S Vaidya Abstract Background: A great deal of the public’s money has been spent on cancer research but demonstrable benefits to patients have not been proportionate. We are a group of scientists and physicians who several decades ago were confronted with bimodal relapse patterns among early stage breast cancer patients who were treated by mastectomy. Since the bimodal pattern was not explainable with the then well-accepted continuous growth model, we proposed that metastatic disease was mostly inactive before surgery but was driven into growth somehow by surgery. Most relapses in breast cancer would fall into the surgery-induced growth category thus it was highly important to understand the ramifications of this process and how it may be curtailed. With this hypothesis, we have been able to explain a wide variety of clinical observations including why mammography is less effective for women age 40–49 than it is for women age 50–59, why adjuvant chemotherapy is most effective for premenopausal women with positive lymph nodes, and why there is a racial disparity in outcome. Methods: We have been diligently looking for new clinical or laboratory information that could provide a connection or corre